No Data
Are Robust Financials Driving The Recent Rally In Chengdu Kanghua Biological Products Co., Ltd.'s (SZSE:300841) Stock?
Three shareholders of chengdu kanghua biological products (300841.SZ) plan to collectively reduce their shareholding by no more than 3.3%.
Chengdu Kanghua Biological Products (300841.SZ) announced that the company recently received notice from shareholders holding more than 5% of the shares, including Kangyue Qiming and other shareholders...
chengdu kanghua biological products (300841.SZ): The construction of the raw material workshop for ACYW135 meningococcal polysaccharide vaccine has been completed.
Gelonghui, November 6th: chengdu kanghua biological products (300841.SZ) stated on the investor interaction platform that the company has completed the construction of the ACYW135 group meningococcal polysaccharide vaccine raw liquid workshop and the "Kanghua biological vaccine production expansion project". They are currently in the supplementary application stage for pharmaceutical production permits, and production can begin after obtaining the production permit.
Kanghua Biology: Report for the third quarter of 2024
Chengdu Kanghua Biological Products (300841.SZ): net income of 0.406 billion yuan in the first three quarters, a year-on-year increase of 10.02%.
Gelonghui October 28th | chengdu kanghua biological products (300841.SZ) announced its third quarter report for 2024, achieving revenue of 1.06 billion yuan in the first three quarters, a year-on-year increase of 7.10%; net income attributable to shareholders of the listed company was 0.406 billion yuan, a year-on-year increase of 10.02%; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was 0.413 billion yuan, a year-on-year increase of 14.52%; basic earnings per share were 3.0697 yuan.
chengdu kanghua biological products (300841.SZ): Since the launch of the company's human diploid cell rabies vaccine, the average sales price has slightly increased.
On October 15th, Kanghua Biological Products (300841.SZ) stated at the investor relations event that the company's sales price for the diploid cell rabies vaccine is mainly determined by the company based on production costs, product positioning, target area consumer levels, and other factors. The bidding price is initially set and after the bidding process or selection process by provincial CDCs in various regions, the final price is confirmed. The average selling price of the diploid cell rabies vaccine has slightly increased since its market launch, with the current selling price at around 300 yuan per dose.
Is Weakness In Chengdu Kanghua Biological Products Co., Ltd. (SZSE:300841) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?
